$78.36
+2.5%Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Outstanding operational efficiency. The company generates substantial profit from core operations.
Strong net margins indicate efficient operations and favorable tax/interest management.
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.
SOLV โข NYSE
| Solventum Corporation Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
REVENUE | ||||||
8.3B | 8.3B | 8.2B | 8.1B | 8.2B | 7.3B | |
GROSS PROFIT | ||||||
(3.9B) | (3.7B) | (3.5B) | (3.4B) | (3.2B) | (3B) | |
4.5B | 4.6B | 4.7B | 4.7B | 4.9B | 4.3B | |
OPERATING INCOME | ||||||
(2.3B) | (3.6B) | (3B) | (3B) | (3B) | (2.9B) | |
(3.1B) | (2.8B) | (2.2B) | (2.2B) | (2.3B) | (2.2B) | |
(739M) | (775M) | (758M) | (767M) | (766M) | (719M) | |
2.2B | 1B | 1.7B | 1.7B | 1.9B | 1.4B | |
PRE-TAX INCOME | ||||||
(347M) | (367M) | (0.0) | (0.0) | (0.0) | (0.0) | |
-347M | -367M | 0.0 | 0.0 | 0.0 | 0.0 | |
-1.5B | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-468M | -431M | -25M | -1M | 3M | 10M | |
1.7B | 605M | 1.7B | 1.7B | 1.9B | 1.4B | |
NET INCOME | ||||||
(157M) | (127M) | (321M) | (349M) | (422M) | (302M) | |
1.6B | 479M | 1.3B | 1.3B | 1.5B | 1.1B |
SOLV - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 27, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 20, 2026 | May 15, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | March 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 20, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 16, 2025 | December 16, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Continue your SOLV research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.